|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metastatic gastric cancer treatment: Second line and beyond显示文摘Advanced gastric cancer(a GC), not amenable to curative surgery, is still a burdensome illness tormenting afflicted patients and their healthcare providers. Whereas combination chemotherapy has been shown to improve survival and tumor related symptoms in the frontline setting, second-line therapy(SLT) is subject to much debate in the scientific community, mainly because of the debilitating effects of GC, which would impede the administration of cytotoxic therapy. Recent data has provided sufficient evidence for the safe use of SLT in patients with an adequate performance status. Taxanes, Irinotecan and even some Fluoropyrimidine analogs were found to provide a survival advantage in this subset of patients. Most importantly, quality of life measures were also improved through the use of adequate therapy. Even more pertinent were the findings involving antiangiogenic agents, which would add measurable improvements without significantly jeopardizing the patients' well-being. Further lines of therapy are cause for much more debate nowadays, but specific targeted agents have shown considerable promise in this context. We herein review noteworthy published data involving the use of additional lines of the therapy after failure of standard frontline therapies in patients with a GC. | Marwan Ghosn Samer Tabchi Hampig Raphael Kourie Mustapha Tehfe | 2016 | World Journal of Gastroenterology2016，22，11： | 10 |
| 2 | Optimum chemotherapy in the management of metastatic pancreatic cancer显示文摘Pancreatic cancer is one of the most devastating solid tumors,and it remains one of the most difficult to treat.The treatment of metastatic pancreatic cancer(MPC)is systemic,based on chemotherapy or best supportive care,depending on the performance status of the patient.Two chemotherapeutical regimens have produced substantial benefits in the treatment of MPC:gemcitabine in 1997;and FOLFIRIONOX in 2011.FOLFIRINOX improved the natural history of MPC,with overall survival(OS)of 11.1 mo.Nab-paclitaxel associated with gemcitabine is a newly approved regimen for MPC,with a median OS of 8.6 mo.Despite multiple trials,this targeted therapy was not efficient in the treatment of MPC.Many new molecules targeting the proliferation and survival pathways,immune response,oncofetal signaling and the epigenetic changes are currently undergoing phaseⅠandⅡtrials for the treatment of MPC,with many promising results. | Marwan Ghosn Hampig Raphael Kourie Fadi El Karak Colette Hanna Joelle Antoun Dolly Nasr | 2014 | World Journal of Gastroenterology2014，20，9： | 7 |
| 3 | Anal cancer treatment:Current status and future perspectives显示文摘Anal cancers(AC)are relatively rare tumors.Their incidence is increasing,particularly among men who have sex with other men due to widespread infection by human papilloma virus.The majority of anal cancers are squamous cell carcinomas,and they are treated according to stage.In local and locally advanced AC,concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil(5-FU)is the current best treatment,while metastatic AC,chemotherapy with 5-FU and cisplatin remains the gold standard.There are no indications for induction or maintenance therapies in locally advanced tumors.Many novel strategies,such as targeted therapies,vaccination,immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC,with promising results in some indications. | Marwan Ghosn Hampig Raphael Kourie Pamela Abdayem Joelle Antoun Dolly Nasr | 2015 | World Journal of Gastroenterology2015，21，8： | 4 |
| 4 | Optimum chemotherapy for the management of advanced biliary tract cancer显示文摘Biliary tract cancers(BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis.The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status.Despite clinical trials studyingmany chemotherapeutic regimens and targeted therapies for the treatment of BTC, the standard of care for advanced BTC remains the combination of gemcitabine with cisplatin.Many new molecules targeting proliferation and survival pathways, the immune response and angiogenesis are currently undergoing phase Ⅰ and Ⅱ trials for the treatment of advanced BTC with promising results. | Marwan Ghosn Hampig Raphael Kourie Elie El Rassy Ralph Chebib Fadi El Karak Colette Hanna Dolly Nasr | 2015 | World Journal of Gastroenterology2015，21，14： | 2 |
| 5 | Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature显示文摘Ampullary carcinoma(AC) is a rare gastrointestinal tumor without clear treatment recommendations.The management of this tumor is usually extrapolated from the treatment of pancreatic,biliary duct and intestinal cancers.Few papers have studied the AC as an independent entity and yet succombs to several limitations.These studies were retrospective single institutional experiences with limited sample sizes recruited over a long period of time.Unlike metastatic ACs where chemotherapy is the only recommended option,localized AC once excised may be approached by either chemotherapy alone or concomitant chemoradiation therapy.In this review,we report the overall survival and recurrence factors of more than 1000 patients from all the studies treating exclusively ACs.We also review the medical treatment of this tumor and conclude to the necessity of multi-institutional randomized controlled studies for AC exclusively. | Marwan Ghosn Hampig Raphael Kourie Elie El Rassy Fady Ghassan Haddad Colette Hanna Fadi El Karak Dolly Nasr | 2016 | World Journal of Gastrointestinal Oncology2016，8，10： | 2 |
| 6 | Dilemma of first line regimens in metastatic pancreatic adenocarcinoma显示文摘Pancreatic cancer is one of the deadliest cancers,ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer(m PC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in the management of m PC, the best choice for first-line treatment has not yet been fully elucidated. Two main strategies have been adopted to enhance treatment efficacy. The first strategy is based on combining non-cross resistant drugs, while the second option includes the development of newer generations of chemotherapy. More recently, two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel(GNP), have both been shown to improve overall survival in comparison with gemcitabine alone, at the cost of increased toxicity. Therefore, the best choice for first line therapy is a matter of debate. For some authors, FOLFIRINOX should be the first choice in patients with an Eastern Cooperative Oncology Group score(0-1) given its lower hazard ratio. However, others do not share this opinion. In this paper, we review the main comparison points between FOLFIRINOX and GNP. We analyze the two pivotal trials to determine the similarities and differences in study design. In addition, we compare the toxicity profile of the two regimens as well as the impact on quality of life. Finally, we present studies revealing real life experiences and review the advantages and disadvantages of possible second-line therapies including their cost effectiveness. | Marwan Ghosn Tony Ibrahim Tarek Assi Elie El Rassy Hampig Raphael Kourie Joseph Kattan | 2016 | World Journal of Gastroenterology2016，22，46： | 2 |
| 7 | Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review显示文摘Metastatic melanoma has long been considered to have a very poor prognosis and to be chemo-resistant. However, a subgroup of patients with metastatic melanoma presents remarkable responses to chemotherapeutic agents, even in the absence of a response to modern targeted therapies and immunotherapies; accordingly, determining predictive biomarkers of the response to chemotherapies for metastatic melanoma remains a priority to guide treatment in these patients. We report a case study of a patient with B-Raf proto-oncogene serine/threonine kinase-mutated metastatic melanoma harbouring many genetic mutations. The patient did not respond to prior targeted therapies or immunotherapies but experienced a dramatic objective radiological and clinical response to subsequent dacarbazine-based chemotherapy. In the era of targeted therapies and immunotherapies for metastatic melanoma, cytotoxic chemotherapies may still represent an interesting therapeutic weapon in a well-deined subgroup of patients presenting with speciic genetic and molecular features. | Aurélien Simon Hampig Raphael Kourie Joseph Kerger | 2017 | Chinese Journal of Cancer2017，36，4： | 2 |
| 8 | Is metastatic pancreatic cancer an untargetable malignancy?显示文摘Metastatic pancreatic cancer(MPC) is one of the most aggressive malignancies, known to be chemo-resistant and have been recently considered resistant to some targeted therapies(TT). Erlotinib combined to gemcitabine is the only targeted therapy that showed an overall survival benefit in MPC. New targets and therapeutic approaches, based on new-TT, are actually being evaluated in MPC going from immunotherapy, epigenetics, tumor suppressor gene and oncogenes to stromal matrix regulators. We aim in this paper to present the major causes rendering MPC an untargetable malignancy and to focus on the new therapeutic modalities based on TT in MPC. | Hampig Raphael Kourie Joseph Gharios Fadi Elkarak Joelle Antoun Marwan Ghosn | 2016 | World Journal of Gastrointestinal Oncology2016，8，3： | 1 |
| 9 | Unusual presentation of nasopharyngeal carcinoma with rectal metastasis显示文摘Nasopharyngeal carcinoma(NPC) is a rare tumour that mainly metastasizes in lymph nodes,bones,lungs and liver.Colorectal metastases of NPC are extremely rare phenomenon and associated with a poor prognosis.We reported here a case of NPC with rectal metastasis,we discussed the treatment modalities and the prognosis after reviewing the similar cases described in the literature. | Malvine Vogel Hampig Raphael Kourie Martine Piccart Yassine Lalami | 2017 | World Journal of Clinical Cases2017，5，5： | 1 |
| 10 | Double pancreatic and gastric adenocarcinomas: A rare association显示文摘 | Hampig Raphael Kourie Nina Markoutsaki Hélène Roussel Gabriel Rahmi Muriel Van der Stiegel Laurent Palazzo Monique Fabre Charles A. Cuenod Olivier Dubreuil Bruno Landi Philippe Rougier Julien Taieb | 2012 | Clinics and Research in Hepatology and Gastroenterology2012，，： | 1 |
| 11 | Gastrointestinal cancers in the era of theranostics: Updates and future perspectives显示文摘Theranostics are one of the practical aspects of personalized medicine.This concept was designed to describe a material combining diagnosis,treatment and follow up of a disease.It evolved and included molecular targeting and nanotechnologies that incorporate both diagnosis and therapeutics.In this editorial,we are presenting briefly the concept and evolution of theranostics,highlighting many applications of theranostics in daily practice and discussing future perspectives and aspects of this model in gastrointestincal cancers. | Marwan Ghosn Hampig Raphael Kourie Samer Tabchi | 2015 | World Journal of Gastroenterology2015，21，28： | 0 |
| 12 | Immunotherapies in sarcoma:Updates and future perspectives显示文摘Sarcomas are malignant tumors that are characterized by a wide diversity of subtypes with various cytogenetic profiles. Despite major treatment breakthroughs, standard treatment modalities combining chemotherapy, radiotherapy, and surgery failed to improve overall survival. Therefore, high expectations are foreseen with immunotherapy upon its maturation and better understanding of its mechanism of action. This paper presents a targeted review of the published data and ongoing clinical trials in immunotherapies of sarcomas, mainly adoptive cell therapies, cancer vaccines and immune checkpoint inhibitors. | Marwan Ghosn Elie El Rassy Hampig Raphael Kourie | 2017 | World Journal of Clinical Oncology2017，8，2： | 0 |
| 13 | Road map for pain management in pancreatic cancer: A review显示文摘Beside its poor prognosis and its late diagnosis, pancreatic cancer remains one of the most painful malignancies. Optimal management of pain in this cancer represents a real challenge for the oncologist whose objective is to ensure a better quality of life to his patients. We aimed in this paper to review all the treatment modalities incriminated in the management of pain in pancreatic cancer going from painkillers, chemotherapy, radiation therapy and interventional techniques to agents under investigation and alternative medicine. Although specific guidelines and recommendations for pain management in pancreatic cancer are still absent, we present all the possible pain treatments, with a progression from medical multimodal treatment to radiotherapy and chemotherapy then interventional techniques in case of resistance. In addition, alternative methods such as acupuncture and hypnosis can be added at any stage and seems to contribute to pain relief. | Marie José Lahoud Hampig Raphael Kourie Joelle Antoun Lana El Osta Marwan Ghosn | 2016 | World Journal of Gastrointestinal Oncology2016，8，8： | 0 |
| 14 | Checkpoint inhibitors in gastrointestinal cancers:Expectations and reality显示文摘Immune checkpoint inhibitors represent revolutionary anti-cancer agents, being rapidly approved in different malignancies and settings. Gastrointestinal(GI) cancers represent a wide variety of tumors with specific characteristics and different responses to various therapeutic alternatives; while some are chemosensitive others are chemo-resistant and only respond to more aggressive cytotoxic regimens, targeted therapies or a combination of both. Preliminary results of immune checkpoint inhibitors in some GI cancers are promising, namely in hepatocellular carcinoma, anal cancers and microsatellite instability high colorectal cancers. An impressive instead of a impressive number of immune checkpoint inhibitors are being evaluated in different indications in GI cancers as single agents or in combination with other agents. We reported in this paper ongoing and published trials evaluating immune checkpoint inhibitors in hepatocellular carcinoma and biliary tract cancers, esophageal, gastric, pancreatic, colorectal and anal cancers and we discussed the future perspectives of these agents in GI cancers. | Hampig Raphael Kourie Samer Tabchi Marwan Ghosn | 2017 | World Journal of Gastroenterology2017，23，17： | 0 |
| 15 | Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer显示文摘Charcot-Marie-Tooth (CMT) neuropathy is the most common hereditary cause of neuropathy.Diagnosis is usually not made during the childhood but in adolescence or late adulthood.It is reported in the literature that some neurotoxic chemotherapeutical agents can reveal an asymptomatic CMT IA hereditary neuropathy.To our knowledge,we report here the first case of CMT IA revealed in a 55-year-old woman after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer.This case stresses again the necessity to obtain a complete personal and familial anamnesis and to perform a neurologic examination before the administration of neurotoxic chemotherapeutical agents to prevent the clinical expression of these hereditary neuropathies. | Hampig Raphael Kourie Nicolas Mavroudakis Philippe Aftimos Martine Piccart | 2017 | World Journal of Clinical Oncology2017，8，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员